Circulating levels of vascular endothelial growth factor and post-stroke long-term functional outcome.
cerebrovascular diseases
functional outcome
inflammation
ischemic stroke
rehabilitation
stroke severity
strokes
vascular endothelial growth factor
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
11
10
2019
revised:
23
12
2019
accepted:
05
01
2020
pubmed:
11
1
2020
medline:
25
8
2020
entrez:
11
1
2020
Statut:
ppublish
Résumé
Vascular endothelial growth factor (VEGF) acts in angiogenesis and neuroprotection, although the beneficial effects on experimental ischemic stroke (IS) have not been replicated in clinical studies. We investigated serum VEGF (s-VEGF) in the acute stage (baseline) and 3 months post-stroke in relation to stroke severity and functional outcome. The s-VEGF and serum high-sensitivity C-reactive protein (hs-CRP) concentrations were measured in patients enrolled in the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS) at the acute time-point (median 4 days, N = 492, 36% female; mean age, 57 years) and at 3 months post-stroke (N = 469). Baseline stroke severity was classified according to the National Institutes of Health Stroke Scale (NIHSS), and functional outcomes (3 months and 2 years) were evaluated using the modified Rankin Scale (mRS), dichotomized into good (mRS 0-2), and poor (mRS 3-6) outcomes. Multivariable logistic regression analyses were adjusted for covariates. The baseline s-VEGF did not correlate with stroke severity but correlated moderately with hs-CRP (r = .17, P < .001). The baseline s-VEGF was 39.8% higher in total anterior cerebral infarctions than in lacunar cerebral infarctions. In binary logistic regression analysis, associations with 3-month functional outcome were non-significant. However, an association between the 3-month s-VEGF and poor 2-year outcome withstood adjustments for age, sex, cardiovascular covariates, and stroke severity (per 10-fold increase in s-VEGF, odds ratio [OR], 2.56, 95% confidence interval [CI] 1.12-5.82) or hs-CRP (OR 2.53, CI 1.15-5.55). High 3-month s-VEGF is independently associated with poor 2-year functional outcome but not with 3-month outcome.
Substances chimiques
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
405-414Subventions
Organisme : John och Brit Wennerströms Stiftelse för Neurologisk Forskning
Organisme : Stiftelsen Lars Hiertas Minne
Organisme : Magnus Bergvalls Stiftelse
Organisme : The Swedish Heart Lung Foundation
ID : 20160316
Organisme : The European Research Council
ID : 681712
Organisme : Edit Jacobson Foundation
Organisme : Emelle Foundation
Organisme : The Yngve Land Foundation
Organisme : The Swedish Stroke Association
Organisme : Grants the Swedish state under the agreement between the Swedish government (ALF agreement)
ID : ALFGBG-720081; -147771; -722371; -715986; -720931
Organisme : Svenska Läkaresällskapet
Organisme : Vetenskapsrådet
ID : 2018-02542
Organisme : The Göteborg Foundation for Neurological Research
Organisme : Rune och Ulla Amlövs Stiftelse för Neurologisk och Reumatologisk Forskning
Organisme : The Torsten Söderberg Foundation
Organisme : Hjärnfonden
ID : FO2017-0243
Informations de copyright
© 2020 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd.
Références
Crafts TD, Jensen AR, Blocher-Smith EC, Markel TA. Vascular endothelial growth factor: therapeutic possibilities and challenges for the treatment of ischemia. Cytokine. 2015;71:385-393.
Hermann DM, Zechariah A. Implications of vascular endothelial growth factor for postischemic neurovascular remodeling. J Cereb Blood Flow Metab. 2009;29:1620-1643.
Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest. 2000;106:829-838.
Manoonkitiwongsa PS, Schultz RL, Whitter EF, Lyden PD. Contraindications of VEGF-based therapeutic angiogenesis: effects on macrophage density and histology of normal and ischemic brains. Vascul Pharmacol. 2006;44:316-325.
Ma Y, Qu Y, Fei Z. Vascular endothelial growth factor in cerebral ischemia. J Neurosci Res. 2011;89:969-978.
Dassan P, Keir G, Jager HR, Brown MM. Value of measuring serum vascular endothelial growth factor levels in diagnosing acute ischemic stroke. Int J Stroke. 2012;7:454-459.
Slevin M, Krupinski J, Slowik A, Kumar P, Szczudlik A, Gaffney J. Serial measurement of vascular endothelial growth factor and transforming growth factor-β1 in serum of patients with acute ischemic stroke. Stroke. 2000;31:1863-1870.
Lopez-Cancio E, Ricciardi AC, Sobrino T, et al. Reported prestroke physical activity is associated with vascular endothelial growth factor expression and good outcomes after stroke. J Stroke Cerebrovasc Dis. 2017;26:425-430.
Matsuo R, Ago T, Kamouchi M, et al. Clinical significance of plasma VEGF value in ischemic stroke - research for biomarkers in ischemic stroke (REBIOS) study. BMC Neurol. 2013;13:32.
Xue L, Chen H, Zhang T, Chen J, Geng Z, Zhao Y. Changes in serum vascular endothelial growth factor and endostatin concentrations associated with circulating endothelial progenitor cells after acute ischemic stroke. Metab Brain Dis. 2017;32:641-648.
Navarro-Sobrino M, Rosell A, Hernandez-Guillamon M, et al. A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis. 2011;216:205-211.
Paczkowska E, Golab-Janowska M, Bajer-Czajkowska A, et al. Increased circulating endothelial progenitor cells in patients with haemorrhagic and ischaemic stroke: the role of endothelin-1. J Neurol Sci. 2013;325:90-99.
Okazaki H, Beppu H, Mizutani K, Okamoto S, Sonoda S. Changes in serum growth factors in stroke rehabilitation patients and their relation to hemiparesis improvement. J Stroke Cerebrovasc Dis. 2014;23:1703-1708.
Arba F, Giannini A, Piccardi B, et al. Small vessel disease and biomarkers of endothelial dysfunction after ischaemic stroke. Eur Stroke J. 2019;4:119-126.
Lee SC, Lee KY, Kim YJ, Kim SH, Koh SH, Lee YJ. Serum VEGF levels in acute ischaemic strokes are correlated with long-term prognosis. Eur J Neurol. 2010;17:45-51.
Jood K, Ladenvall C, Rosengren A, Blomstrand C, Jern C. Family history in ischemic stroke before 70 years of age: the Sahlgrenska Academy Study on Ischemic Stroke. Stroke. 2005;36:1383-1387.
Åberg ND, Olsson S, Åberg D, et al. Genetic variation at the IGF1 locus shows association with post-stroke outcome and to circulating IGF1. Eur J Endocrinol. 2013;169:759-765.
Pedersen ED, Waje-Andreassen U, Vedeler CA, Aamodt G, Mollnes TE. Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol. 2004;137:117-122.
Youn CS, Choi SP, Kim SH, et al. Serum highly selective C-reactive protein concentration is associated with the volume of ischemic tissue in acute ischemic stroke. Am J Emerg Med. 2012;30:124-128.
Åberg D, Jood K, Blomstrand C, et al. Serum IGF-I levels correlate to improvement of functional outcome after ischemic stroke. J Clin Endocrinol Metab. 2011;96:E1055-E1064.
Vandenbroucke JP, Von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297.
Gray LJ, Ali M, Lyden PD, Bath PM. Virtual International Stroke Trials Archive C. Interconversion of the National Institutes of Health Stroke Scale and Scandinavian Stroke Scale in acute stroke. J Stroke Cerebrovasc Dis. 2009;18:466-468.
Åberg ND, Åberg D, Jood K, et al. Altered levels of circulating insulin-like growth factor I (IGF-I) following ischemic stroke are associated with outcome - a prospective observational study. BMC Neurol. 2018;18:106.
Olsson S, Jood K, Blomstrand C, Jern C. Genetic variation on chromosome 9p21 shows association with the ischaemic stroke subtype large-vessel disease in a Swedish sample aged ≤70. Eur J Neurol. 2011;18:365-367.
Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 1993;24:35-41.
Olsson S, Holmegaard L, Jood K, et al. Genetic variation within the interleukin-1 gene cluster and ischemic stroke. Stroke. 2012;43:2278-2282.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-1526.
Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373-1379.
Malmivaara A, Meretoja A, Peltola M, et al. Comparing ischaemic stroke in six European countries. The Euro HOPE register study. Eur J Neurol. 2015;22:284-291, e25-6.
Hallström B, Jönsson AC, Nerbrand C, Petersen B, Norrving B, Lindgren A. Lund stroke register: hospitalization pattern and yield of different screening methods for first-ever stroke. Acta Neurol Scand. 2007;115:49-54.
Menezes NM, Ay H, Wang Zhu M, et al. The real estate factor: quantifying the impact of infarct location on stroke severity. Stroke. 2007;38:194-197.
Mattlage AE, Rippee MA, Sandt J, Billinger SA. Decrease in insulin-like growth factor-1 and insulin-like growth factor-1 ratio in the first week of stroke is related to positive outcomes. J Stroke Cerebrovasc Dis. 2016;25:1800-1806.
Pang Q, Zhang H, Chen Z, et al. Role of caveolin-1/vascular endothelial growth factor pathway in basic fibroblast growth factor-induced angiogenesis and neurogenesis after treadmill training following focal cerebral ischemia in rats. Brain Res. 2017;1663:9-19.
Abo-Ramadan U, Durukan A, Pitkonen M, et al. Post-ischemic leakiness of the blood-brain barrier: a quantitative and systematic assessment by Patlak plots. Exp Neurol. 2009;219:328-333.
Ewing JR, Brown SL, Lu M, et al. Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor. J Cereb Blood Flow Metab. 2006;26:310-320.